Agoracom Blog

VIDEO – FansUnite $58,000,000 Acquisition “Most Significant Milestone To Date”. Brings $13M Revenues, $6M EBIDTA And Partners Such As DraftKings ++

Posted by AGORACOM-JC at 5:10 PM on Tuesday, November 23rd, 2021
This image has an empty alt attribute; its file name is fans-square-300x300.jpg

FansUnite Entertainment $FANS $FUNFF is a global sports and entertainment company, focusing on technology for online gambling. Specifically, they have produced a one-of-a-kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform operates multiple B2C brands and B2B software for the online gambling industry.  More than just talk FANS has:

  • 300,000+ registered members
  • $CDN 350,000,000 in betting volume over the last 3 years
  • Gambling licenses in the highly coveted U.K. and Malta
  • A successful $25,000,000 raise earlier this year to arm the company for acquisitions.

Today they announced a $USD 58,000,000 acquisition that can best be described by CEO Scott Burton in this powerful quote: 

“The acquisition of American Affiliate represents the most significant milestone for FansUnite to date,” said Scott Burton, CEO of FansUnite Entertainment. “This transformative transaction will provide us further access to the lucrative U.S. regulated sports betting and online gambling market while generating accretive, high-margin revenue, expanding our leadership team, and accelerating the growth of our company’s footprint in the global gambling market.” 

Some of the highlights of this acquisition are as follows:

  • Revenue and EBITDA Growth: American Affiliate has produced trailing 12 months unaudited revenue and EBITDA of US$13.1 million and US$6.0 million respectively.
  • High-Value Customer Base: American Affiliate’s assets have generated over 150,000 new depositing customers for legal U.S. online betting operators.
  • Partnerships with Tier-One Sportsbooks: Partnerships with leading sportsbooks and casinos including BetMGM, DraftKings, FanDuel, PointsBet, Underdog Fantasy, WynnBet, and more.
  • Strong Alignment with Existing Management and Shareholders: Consideration shares to be issued at a 42% premium to market price with share restrictions over a three-year period
  • World-Class Executive Team: Tier-one executive and management team with a history of success and scale in the U.S. gaming market
  • Leading Intellectual Property Portfolio: Category-leading portfolio of proprietary technology.

Watch this great interview with CEO Scott Burton.

VIDEO – Liquid Avatar Announces First Age Verifiable Metaverse Components With Cannabis and Vegas Partnerships On Aftermath Islands. LA Comic Con “Surprises” Planned For 100,000 + Attendees

Posted by AGORACOM-JC at 8:48 AM on Thursday, November 18th, 2021
Liquid avatar logo v1 nk

The internet has evolved from Web 1.0 (dot-com read only) back in the 90’s to Web 2.0 (read and write) over the last 15 years to the current emergence of Web3 … which I can best describe as entering the Matrix (for some older investors) OR Ready Player 1 for our younger investors.  

The technical term is the Metaverse.  It’s already a $30B market BUT we haven’t seen anything yet based on the following: 

  • According to Strategy Analytics, the global metaverse market size is projected to increase ~ 1,000% to $280 billion by 2025 from $30.7 billion in 2021 SOURCE  … but we think that’s a very conservative estimate
  • Bloomberg Intelligence believes the Metaverse can reach $800 billion by 2024.
  • South Korea’s biggest asset manager, Samsung Asset Management, recently launched a metaverse fund.

IS THE METAVERSE HERE

It was always coming but we just didn’t know when because we needed two things to happen – the evolution of technology and acceptance.  

The technology is now here thanks to AR, VR, Blockchain and the rise of NFTs, which Liquid Avatar has been at the forefront of since Day 1.

Acceptance was always a bit more of a wildcard because it is a pretty big shift – but the Covid-19 pandemic was the catalyst that drove the internet to the next stage of its evolution – the ‘Metaverse’ where cyberspace becomes more of an interactive 3D space with commerce and networking alongside content, much like the worlds in popular games such as Fortnite and Roblox,

Roundhill Investments, a major ETF sponsor focused on thematic and sector-specific investing stated “We Believe More Virtual Platforms Will Emerge … New virtual platforms will emerge, and they will likely exceed today’s leaders”

ENTER LIQUID AVATAR METAVERSE ENTRY WITH AFTERMATH ISLANDS

Two weeks ago Liquid Avatar announced that it’s Sale of Virtual Land NFTs in Aftermath Islands Metaverse Went Live .  Though we don’t have official numbers yet, we do know that all virtual land in “Musk Manor” and “Bitcoin Bay” sold out pretty fast, so it’s safe to say that Aftermath Islands is off to great success.

With that kind of success, it’s no wonder $LQID is planning to showcase its Metaverse chops at what might be the biggest Comic Con of the year as we come out of COVID – LA Comic Con – where they were named as the Digital Innovation Partner back on October 26.  Subsequently $LQID announced announced Hosting a Metaverse Mainstage Panel at Los Angeles Comic Con, Featuring Aftermath Islands ..where it will also has over 1,500 square feet of prime floor space that will showcase NFT subsidiary Oasis Studios, Aftermath Islands, comic and graphics art partner Apex Comics Group … and as yet to be announced “surprises”.

This week $LQID added another great element to Aftermath Islands, the first ever age verified islands as follows:

Aftermath Islands Partners with Primo Gardens to Create Cannabis Cove the First Metaverse Island Group Dedicated to Cannabis Sector

Aftermath Islands Partners with Vegas.com Creator to Launch Vegas Island in the Metaverse

These are powerful initiatives because the genesis of $LQID is biometrically verified digital identity … giving the Company a substantial advantage in the race towards building the Metaverse.

If you’re a small cap investor that wants exposure to The Metaverse, make sure to watch this great interview with CEO David Lucatch.

VIDEO – AI/ML Innovations $AIML $AIMLF set to Make Waves w/ Health Gauge Partnership, U.S. Launch for AI Rx $PFM.ca $DM.ca $ADK.ca

Posted by AGORACOM-AB at 3:09 PM on Tuesday, October 26th, 2021
AI/ML Innovations Inc.

AI/ML Innovations is capitalizing on the burgeoning areas of artificial intelligence (AI), cloud computing and machine learning (ML), with an initial focus on emerging companies in the digital healthcare space.

Its key subsidiary, Health Gauge, is a leading digital health solutions provider that’s disrupting the traditional healthcare industry by providing AI innovations and services that improve health outcomes, while at the same time reducing costs and stresses on the overburdened healthcare infrastructure.

Its patent-pending solution is a bespoke personal health monitoring and management system, combining the latest wearable health monitors with sophisticated software tools.

Health Gauge provides for a secure and trusted means for clients to engage clinical resources and health coaching as a regular part of their care process and ongoing health management. Its robust, real-time data capture capability provides fast feedback, resulting in better recovery outcomes and healthy living objectives through the ability to make immediate and better health choices.

In addition to Health Gauge, AI/ML also has a strategic partner in Tech2Heal, a France-based global provider of proprietary digital mental health and wellness products.

In late September, AI/ML announced that it had completed its transaction to acquire a significant interest in Tech2Heal (dba Tech2Health), and that Tech2Heal was readying its remote patient monitoring platform for deployment.

Now, AI/ML Innovations & Tech2Heal’s AI Rx joint venture is preparing for imminent launch into the U.S. market, with a basket of wellness and health-tech products and services designed to improve an individual’s mental health and well-being, and utilizing a unique blend of proprietary digital assets, remote live counselling, and a physical wellness center.

We caught up with Tim Daniels, AI/ML’s Executive Chairman, to discuss the firm’s progress…

VIDEO – TAAT Global Alternatives $TAAT $TOBAF “Beyond Tobacco” Eyes $10m Investment Boost, Preps Branded Apparel for Q1 2022 $MO $PM $BATS

Posted by AGORACOM-AB at 9:23 AM on Monday, October 18th, 2021

To understand the value proposition of TAAT, you first have to understand some recent massive trends in the Consumer Packaged Goods (CPG) space:

  • Non-alcoholic beer has grown to an $18bn USD market
  • The plant-based meat market is projected to hit $74bn USD By 2027

What they have in common is providing consumers of the original products with the exact same experience (taste, smell, etc.) without the negative parts of the original products.

TAAT has developed a nicotine-free and tobacco-free smoking experience known as TAAT™, which already launched in the USA. TAAT™ Beyond Tobacco™ cigarettes mimic those experiences without nicotine or tobacco.

Engineered to closely emulate the sensory components to provide the closest experience of smoking a tobacco cigarette – a product that tastes and smells just like tobacco – but without the nicotine.

October has seen a flurry of news for the company: 

OCT 5: The company reported Q3 2021 Financial Results:

1. Gross revenue grew to an all-time high of $1,305,358 in Q3 2021, an increase of 1,956% YOY
2. Gross profit for Q3 2021 was $781,226 with a gross profit margin of 59.84%
3. Healthy balance sheet with $10,174,001 in working capital

OCT 6: TAAT Announced it Would Be Releasing A Branded Merchandise Line of Apparel and Accessories in Q1 2022

OCT 13: TAAT Announced A Follow-On Private Placement for CAD $10m

We sat down with CEO Setti Coscarella for a company update…

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:57 AM on Saturday, October 16th, 2021

A weekly summary of Novamind news and media, including the announcement we have been granted DEA licenses for psilocybin research.

October 12, 2021

Psychedelics, Mindfulness, and Contemplative Practices

In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. 

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

October 15, 2021

Why Palliative Care?

Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.

October 15, 2021

The Most Effective Pairing

In a recent interview with Technology Networks, Dr. Reid Robison spoke about the powerful combination of psychedelics and psychotherapy. 

October 14, 2021

A Key Step in Hosting Contracted Clinical Trials for Psilocybin Research

Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.

October 7, 2021

“We’re Just Scratching the Surface of What Can Be Done.”

Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.

Don’t forget to download the third edition of PSYCH’s “The Psychedelics as Medicine Report”, featuring an expert interview with Dr. Robison.

View all media

Novamind Granted DEA Licenses for Psilocybin Research

We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.

“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”

Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.

“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”

To learn more about Novamind’s clinical research division, visit www.cedarclinicalresearch.com.

¹ https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630
² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/

October 13, 2021

View all press releases

How COVID-19 Opened the Door to a New Era in Psychedelic Medicine

Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.

Will Australia Take a Lead in Psychedelic Therapy?

Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” 
Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.

The New Cannabis?

Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Valeo Pharma Agreement Supports $30M Annual Revenue Target From Blood Thinner Product Alone

Posted by AGORACOM-JC at 4:12 PM on Wednesday, October 13th, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.  

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.   

Q3 Highlights:  

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

In today’s announcement, Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada.

Highlighted by the following;

  • 2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
  • The 2 multi-year product listings commenced on October 1, 2021
  • The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario

The agreement above supports $30M annual revenue target From blood thinner product alone!

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, October 9th, 2021

A weekly summary of Novamind news and media, including the launch of our new Psychedelic Palliative Care program.

October 5, 2021

Self Compassion, Forgiveness, and Judgment Detox

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

October 6, 2021

Novamind Today and Into the Future

CEO Yaron Conforti at the Benzinga Healthcare Small Cap Conference on the progress we’ve been making to increase access to psychedelic medicine.

October 6, 2021

Addressing Mental Health through Emerging Therapies Panel

CEO Yaron Conforti joins a panel of industry leaders at the Benzinga Healthcare Small Cap Conference for this informative discussion.

October 7, 2021

Dr. Reid Robison Keynote at PSYCH Investor Summit

Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.

In addition, we are pleased to be featured in the third edition of PSYCH’s “The Psychedelics as Medicine Report”.

View all media

Novamind Launches New Psychedelic Palliative Care Program

We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.

Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.

“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”

Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.

Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.

“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”

To learn more about the Palliative Program, visit www.novamind.ca/psychedelic-palliative-care

October 7, 2021

Novamind to Present at LD Micro and KCSA Conferences

We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

October 8, 2021

View all press releases

The Psychedelics Industry Could Offer a Whole New Approach to Work

In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”

Psychedelics: Psychiatry of the Future

Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.

How Psychedelics are Returning to the World of Medicine

“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

VIDEO – Fobi AI To Acquire PassWallet, A Leading Android Wallet Pass Issuer With 6M+ Downloads

Posted by AGORACOM-JC at 4:32 PM on Thursday, October 7th, 2021
Fobi AI Inc.

FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space.  From that core technology they have built a technology stack on top of it that is second to none.

They have created multiple successful applications that, for the purposes of this interview, includes their venue management platform that has been deployed at multiple NCAA tournaments, a recent MGM Resorts Championship PGA Event in Las Vega and most recently signed a deal to bring their venue management solutions to the Canadian Hockey League, the world’s largest development hockey league with 9 Million Fan Visits in 2019.  

In this interview we discuss today’s news: Fobi Announces Acquisition of PassWallet, A Leading Android Wallet Pass Issuer With 6,000,000+ Downloads. Deal To Provide Near-Term and Long-Term Revenue Growth

How important is this acquisition? CEO Rob Anson says it best: 

“This represents a key achievement for Fobi and its shareholders. This acquisition of PassWallet positions Fobi as an up and coming leader in the digital wallet space. The company has made great strides this year and this key strategic development positions us extremely well, enabling us to leverage and monetize on a standard ARPU model (average revenue per user). With over 6 million downloads currently, management believes that by leveraging our artificial intelligence and data solutions as well as the integration of Fobi’s marketing power together with the global wallet pass growth rates, that this number will grow significantly in 2022. Coupled with further untapped opportunity and an addressable market of over 150 countries that are currently not serviced by Google Pay, management anticipates that with this acquisition Fobi is now well positioned to expand into the FinTech space.” 

Sit back and watch this powerful interview with CEO Rob Anson AND… Fobi SVP of Corporate Strategy & Corporate Development Richard Lee.

VIDEO – Liquid Avatar $LQID Digital Identity Platform Goes Commercial With Age Verification Products For 8,000 Convenience Stores In Ontario

Posted by AGORACOM-JC at 10:01 AM on Wednesday, October 6th, 2021

12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again.

Moreover, the platform also provides both businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).

It sounded great … and definitely sounded like something you could see starting to happen 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.

1.  In March of this year, Google validated the $LQID business model with this stunning announcement:

 Google announces major shift away from precision-targeting of ads based on everything you do on the internet

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

With this news, the data privacy and monetization game is underway and LQID sitting in a great position within the industry and the dominant position within the small cap world.  

BUT THAT’S NOT ALL


2.  In May of this year, The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments.

Then came the news all Liquid Avatar investors were waiting for: 

Ontario Releases Technology and Standards for Digital Identity which includes: 

  • the creation of a new data authority; 
  • the introduction of a new government-issued digital ID that lets people prove who they are both online and in person.

These 2 announcements out of Google and the Ontario Government officially put both business and government in the digital identity and credentials game.  There is no looking back.

ENTER LIQUID AVATAR – WORKING WITH ONTARIO GOVERNMENT

Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies .  More than just a good idea, $LQID issued a press release announcing the following:

“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation”

AND

“Liquid Avatar Technologies has been a part of the ongoing consultations around the province’s plan to introduce a digital identification credential by the end of 2021”

ENTER LIQUID AVATAR – OUT OF DEVELOPMENT AND INTO COMMERCIALIZATION WITH 8,000 CONVENIENCE STORES

This morning $LQID released major news on the commercialization side whose title speaks for itself:

Liquid Avatar Partners With Ontario Convenience Stores Association To Provide Digital Age Verification To 8,000 Stores

According to CEO Lucatch, this announcement represents a major inflection point as it signals a shift from development to commercialization, with many more potential deals in discussion.

LQID IS THE LEADING SMALL CAP COMPANY IN MASSIVE PARADIGM SHIFT TOWARD DIGITAL IDENTITY, PRIVACY AND MONETIZATION

Make no mistake about it.  This is a simply massive paradigm shift and $LQID isn’t going to tackle this on its own.  The Company is a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.

Suddenly it is getting easy to see the genius of Liquid Avatar.

Watch this great interview with CEO David Lucatch.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:29 AM on Saturday, October 2nd, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our 6ᵗʰ clinic in Murray, Utah.

September 28, 2021

Fear, Suffering, and the Value of Struggle

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss fear, the difference between pain vs. suffering, and the value of struggle in life.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

September 28, 2021

Dr. Reid Robison presents at the Life Sciences Investor Forum

In case you missed the presentation from our Chief Medical Officer, a recording of the presentation is now available for viewing here.

October 1, 2021

The Rapid Expansion Continues

Novamind CEO, Yaron Conforti, sits down with Agoracom to discuss opening our 6ᵗʰ clinic in Murray, UT and the broader vision for the company.

View all media

Novamind Opens 6ᵗʰ Integrative Psychiatry Clinic, Adds 3ʳᵈ Clinical Research Site

We are pleased to announce the opening of our sixth integrative psychiatry clinic. The clinic is in Murray, Utah (the “Murray Clinic”).

The Murray Clinic also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population. The Company anticipates 65,000 visits to its clinics this year.

“Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment,” explained Yaron Conforti, CEO and Director. “We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”

The Murray Clinic is the latest in Novamind’s ongoing clinic expansion, with two additional clinics slated to open in Utah by the end of 2021. The Salt Lake City location is scheduled to open in October, while the Park City location will open in November to accommodate the construction of the Company’s new flagship clinic design.

Learn more about Novamind’s clinical research division here.

September 30, 2021

View all press releases

How Psychedelics Changed my Life

The evidence continues to grow in support of psychedelic medicine. In a piece for the Independent, Jonathan Sabbagh writes about how psychedelics, and ketamine-assisted psychotherapy in particular, changed his life. “For the first time, I understood the truth. My burnout wasn’t an end in itself. It was a symptom of a previously undiagnosed severe case of post-traumatic stress disorder.”

The Science of Psychedelic Therapy Breaks on Through

Axios breaks down why psychedelics matter, where they stand and what to watch for in the future. “Scientific studies of psychedelic therapies may be entering a new, broader phase thanks to more interest and funding from federal governments.” We will continue to research psychedelics and other innovative therapies at Cedar Clinical Research. CCR’s research sites are co-located with Novamind’s Cedar Psychiatry clinics allowing for large client population recruitment and providing clients access to innovative research stage treatments. And just this last week, we announced the opening of a new research site and clinic.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]